References
- ShiYAuJSThongprasertSA prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)J Thorac Oncol20149215416224419411
- ChouguleAPrabhashKNoronhaVFrequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicityPLoS One2013810e7616424124538
- RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
- MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
- PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
- SyahruddinEWulandariLSri MuktiatiNUncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patientsLung Cancer20189253429615847
- NoronhaVChoughuleAPatilVMEpidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatmentOnco Targets Ther2017102903290828652772
- Beau-FallerMPrimNRuppertAMRare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT networkAnn Oncol201425112613124285021
- ArrietaOCardonaAFCorralesLThe impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancerLung Cancer201587216917525558790
- De PasTToffalorioFManzottiMActivity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutationsJ Thorac Oncol20116111895190121841502
- TuHYKeEEYangJJA comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancerLung Cancer20171149610229173773
- PatilVMNoronhaVJoshiAPhase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaESMO Open201721e00016828761735
- ShiJYangHJiangTUncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapyChin J Cancer Res201729654355229353977
- WuJYYuCJChangYCYangCHShihJYYangPCEffectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancerClin Cancer Res201117113812382121531810
- YangJCSequistLVGeaterSLClinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6Lancet Oncol201516783083826051236